VKH
BLRX

Virtu KCG Holdings’s BioLineRX BLRX Stock Holding History

Virtu KCG Holdings’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-292
Closed -$168K – 2901
2017
Q1 		$168K Buy
292
+256
+711% +$165K ﹤0.01% 2512
2016
Q4 		$20K Sell
36
-216
-86% -$134K ﹤0.01% 3230
2016
Q3 		$174K Buy
252
+203
+414% +$108K ﹤0.01% 2437
2016
Q2 		$24K Sell
49
-177
-78% -$99K ﹤0.01% 2775
2016
Q1 		$138K Buy
+226
New +$142K ﹤0.01% 2238
2015
Q3 		– Sell
-97
Closed -$154K – 3344
2015
Q2 		$154K Buy
97
+48
+98% +$59.4K ﹤0.01% 2733
2015
Q1 		$62K Buy
+49
New +$60.3K ﹤0.01% 2779
2014
Q3 		– Sell
-20
Closed -$25K – 3592
2014
Q2 		$25K Sell
20
-11
-35% -$13.8K ﹤0.01% 3509
2014
Q1 		$41K Buy
31
+9
+41% +$14.8K ﹤0.01% 3360
2013
Q4 		$37K Buy
22
+4
+22% +$6.45K ﹤0.01% 3650
2013
Q3 		$24K Buy
+18
New +$21.3K ﹤0.01% 3600

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu KCG Holdings's BLRX Position: Q2 2017 in Review

Virtu KCG Holdings sold out of BioLineRX (BLRX) in Q2 2017, closing a stake of 292 shares — an estimated $168K sold.

Virtu KCG Holdings first reported a position in BLRX in Q3 2013 and held it in 11 quarters. The position peaked at $174K in Q3 2016. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2017.

  • Virtu KCG Holdings reported no remaining BioLineRX position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 292 BioLineRX shares in Q2 2017, an estimated $168K.
  • Virtu KCG Holdings first reported a position in BioLineRX in Q3 2013 and held it in 11 quarters.
  • Virtu KCG Holdings's BioLineRX position peaked at $174K in Q3 2016.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.